TAK vs. TEVA: Takeda Pharmaceutical vs. Teva Pharmaceutical Stock Comparison

Company Profile

Takeda Pharmaceutical (TAK) and Teva Pharmaceutical (TEVA) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Both Takeda Pharmaceutical (TAK) and Teva Pharmaceutical (TEVA) trade as ADRs — their core financials are comparable, but keep FX, depositary-program fees, and dividend withholding in view for each.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Takeda Pharmaceutical (TAK) reports a negative beta of -0.01, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Teva Pharmaceutical (TEVA) has a non-negative beta of 0.96.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Teva Pharmaceutical (TEVA) at 6.65% sits in the top ROE quartile, while Takeda Pharmaceutical (TAK) at 0.56% is closer to the peer norm — stronger capital efficiency for TEVA.

Both Takeda Pharmaceutical (TAK) at 0.87% and Teva Pharmaceutical (TEVA) at 2.94% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.

Both Takeda Pharmaceutical (TAK) at 24.55% and Teva Pharmaceutical (TEVA) at 27.40% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Teva Pharmaceutical (TEVA) at 4.31% is around its peer norm for revenue growth, while Takeda Pharmaceutical (TAK) at -1.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Only one side can be read here: Takeda Pharmaceutical (TAK) reports EPS growth of 77.96%, ranked against its industry; Teva Pharmaceutical (TEVA) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Takeda Pharmaceutical (TAK) at 1.15 and Teva Pharmaceutical (TEVA) at 0.95 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both balance sheets lean debt-heavy versus peers, but TEVA is more stretched: Takeda Pharmaceutical (TAK) at 0.72 sits in the higher-leverage quartile and Teva Pharmaceutical (TEVA) at 2.13 is above its industry benchmark range.

Financial Strength Metrics

Dividends

Teva Pharmaceutical (TEVA) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Takeda Pharmaceutical (TAK) reports a yield of 953.28%, ranking against industry peers normally.

Takeda Pharmaceutical (TAK) reports payout ratio above 100% at 426.53%, meaning dividends exceeded current-period earnings; Teva Pharmaceutical (TEVA) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

Both Takeda Pharmaceutical (TAK) at 300.29 and Teva Pharmaceutical (TEVA) at 99.09 trade above their industries’ P/E ratio peer ranges, pointing to unusually expensive trailing earnings relative to peers.

Both Takeda Pharmaceutical (TAK) at 0.01 and Teva Pharmaceutical (TEVA) at 2.89 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.

Takeda Pharmaceutical (TAK) at 1.43 sits in the lower P/B ratio quartile against book while Teva Pharmaceutical (TEVA) at 6.23 is valued near its industry’s middle — TAK is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics